Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Glomerulonephritis, Membranoproliferative

• An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
• Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
• Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
• Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
• Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy
• A Proof of Concept Study for a 12 Month Treatment in Patients With C3 Glomerulopathy (C3G) or Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
• Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies
• A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)
• Effect of Rituximab in Treatment of Membranoproliferative Glomerulonephritis
• A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGN
• Daratumumab in Treatment of PGNMID and C3 GN
• TP10 Use in Patients With C3 Glomerulopathy (C3G)
• Eculizumab in Primary MPGN
• Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
• Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
• Sulodexide Treatment in Patients With Dense Deposit Disease
• Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
• BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis